

**Tertiary Epimutations – A Novel Aspect of Epigenetic Transgenerational Inheritance Promoting Genome Instability**

John R. McCarrey\*, Jake D. Lehle, Seetha S. Raju, Yufeng Wang,  
Eric E. Nilsson, and Michael K. Skinner

**\*Correspondence:** John R. McCarrey  
Department of Biology  
University of Texas at San Antonio  
San Antonio, TX, 78249  
Email: [John.McCarrey@utsa.edu](mailto:John.McCarrey@utsa.edu)  
Phone: 210-458-4507

## **Abstract**

Exposure to environmental factors can induce the epigenetic transgenerational inheritance of disease. Alterations to the epigenome termed “epimutations” include “primary epimutations” which are epigenetic alterations in the absence of genetic change and “secondary epimutations” which form following an initial genetic change. To determine if secondary epimutations contribute to transgenerational transmission of disease following in utero exposure to the endocrine disruptor vinclozolin, we exposed pregnant female rats carrying the *lacI* mutation-reporter transgene to vinclozolin and assessed the frequency of mutations in kidney tissue and sperm recovered from F1 and F3 generation progeny. Our results confirm that vinclozolin induces primary epimutations rather than secondary epimutations, but also show that some primary epimutations can predispose a subsequent accelerated accumulation of genetic mutations in F3 generation descendants. We propose the existence of “tertiary epimutations” which are initial primary epimutations that promote genome instability leading to an accelerated accumulation of genetic mutations.

## Introduction

Since the initial report of the induction of epigenetic transgenerational inheritance of adult-onset disease in F3 generation progeny from an F0 generation gestating female rat exposed to the endocrine disruptor vinclozolin<sup>1</sup>, there have been numerous reports of similar effects caused by exposure of fetuses or adults to a variety of different environmental factors<sup>2, 3</sup>. These environmental factors include various toxicants, including many different endocrine disruptors, nutrition effects including famine, caloric restriction, high fat diets or folate deficiencies, and other stressors such as drought, smoking, alcohol or heat. Exposure of fetuses to these agents in utero, or of adults to these environmental factors, is associated with transgenerational increases in the incidence of adult-onset disease or abnormalities impacting the reproductive systems and fertility in both sexes, the immune system, kidney function, the prostate, obesity, cardiovascular function, growth, insulin sensitivity, glucose tolerance, pulmonary function, neuronal function and social behavior, among other effects<sup>3</sup>. These reports have revealed a novel etiology of adult-onset disease and a mechanism underlying the developmental origins of health and disease (DOHAD)<sup>4</sup>. In addition, these observations suggest that the phenomenon of epigenetic transgenerational inheritance of disease is significantly more extensive than previously thought.

While it is not surprising that exposure to environmental factors or toxicants can alter the epigenome, especially during key developmental periods when epigenetic reprogramming is taking place<sup>5</sup>, it is surprising that such

alterations, known as epimutations, can persist over multiple generations in the absence of any further exposure to the disruptive agent<sup>6, 7, 8</sup>. Persistence of abnormalities for one or two generations following in utero exposure may simply reflect toxicity related effects induced by direct exposure of an F0 generation female, an F1 generation fetus, and/or the germ cells within that fetus that will give rise to the F2 generation. This phenomenon has been termed a “multigenerational exposure”<sup>9</sup> or more recently “intergenerational inheritance”<sup>10</sup>, but, in fact, does not really represent true “inheritance” at all if it is limited to direct exposure toxicity effects. However, transmission of phenotypes through three or more generations following a single transient exposure to the causative agent requires some mechanism of transgenerational inheritance<sup>1, 7, 11</sup>. Epimutations induced by certain effects, for example the use of assisted reproductive technologies (ART), have been shown to be corrected by normal germline-specific epigenetic reprogramming such that they are detected in the F1 generation, but are not transmitted to subsequent generations<sup>12</sup>. These are examples of intergenerational epimutations that are not transgenerational. This begs the question of how epimutations caused by exposure to certain environmental factors, such as endocrine disruptors, during critical windows of development are able to avoid subsequent correction by germline epigenetic reprogramming and persist over multiple generations via transgenerational inheritance.

One potential explanation for the observed transgenerational transmission of epimutations induced by a single exposure to vinclozolin or similar agents in

utero is that this exposure could promote the formation of genetic mutations that impact epigenetic programming, such that the phenotype of these mutations is manifest as epimutations, but the underlying source of these defects is one or more genetic mutations. Indeed, two distinct types of epimutations have been previously described<sup>13</sup>. “Primary epimutations” are epigenetic aberrations that occur in the absence of any genetic change and are propagated via mitosis to daughter cells or via meiosis to subsequent generations on the basis of epigenetic rather than genetic transmission. “Secondary epimutations” are those that form as a consequence of, and thus subsequent to, an initial genetic change (mutation), and can therefore be transmitted on the basis of genetic transmission of the initial mutation or on the basis of epigenetic transmission of the subsequent epimutation, or both. Primary epimutations in the germ line would have the potential to be corrected by germline epigenetic reprogramming, whereas secondary epimutations would not be corrected so would be transmitted transgenerationally as genetic traits. Thus to understand the mechanism of epigenetic transgenerational inheritance, it is important to distinguish between primary and secondary epimutations.

Mutation-reporter transgenes provide a convenient and sensitive approach to assess the frequency of genetic mutations. Such systems can facilitate testing of tens or hundreds of thousands of copies of a reporter transgene to accurately determine the frequency of point mutations in this gene without the need to sequence most of these copies. One of the most extensively studied mutation-reporter systems is the “Big Blue” rodent system originally developed by

Stratagene (now part of Agilent) in the 1990s<sup>14, 15</sup>. This approach provides a method to examine the frequency of mutations accumulated in a transgene that is integrated into the same genomic location in all cells, but is not expressed in any cell type of the animal so does not impact the function of those cells in any way. Specifically, the Big Blue system is based on the colorimetric detection of expression of the *lacZ* reporter gene as an indicator of mutations that have occurred in the *lacI* (repressor) gene. Copies of the transgene expressing the mutant phenotype are sequenced to confirm the presence and type of the relevant mutation in the *lacI* gene and to identify clonal mutations which are counted as a single mutagenic event regardless of how many times they are detected in the same sample.

To determine if in utero exposure to vinclozolin leads to the direct induction of genetic mutations, and, thus, potentially to the induction of secondary epimutations, we exposed pregnant female Big Blue Rats carrying the *lacI* mutation-reporter transgene to vinclozolin as previously described<sup>1, 4</sup> and compared the frequency of mutations in the *lacI* mutation-reporter transgene in kidney tissue and sperm recovered from F1 generation offspring of vinclozolin-treated or control (vehicle-treated) dams. In addition, we bred F1 generation offspring to generate both vinclozolin- and control-lineage F2 generation and subsequently F3 generation descendants as described<sup>3, 16</sup>, and analyzed the frequency of spontaneous mutations in kidney and sperm cells from the F3 generation progeny as well. Our results reveal the unexpected finding of a third type of epimutation which we term “tertiary epimutations.” Tertiary epimutations

are distinct from primary or secondary epimutations and have the potential to contribute to epigenetic transgenerational inheritance.

## Results

*Exposure to vinclozolin in utero does not induce an increase in the frequency of point mutations in F1 generation offspring* – Frequencies of point mutations detected in kidney and sperm cells from F1 generation offspring of dams exposed during pregnancy to either vehicle (DMSO) plus vinclozolin (vinclozolin-lineage animals) or vehicle alone (control-lineage animals) are shown in Table 1. No significant differences in frequencies of mutations were observed between vinclozolin- and control-lineage kidney or sperm samples, respectively, except for one vinclozolin-lineage sperm sample (marked with an asterisk in Fig. 1A) in which we detected a mutation frequency that was significantly lower than the mean frequency of the F1 generation control-lineage sperm samples ( $p=0.0352$ ). Previous studies in the mouse revealed enhanced maintenance of genetic integrity in germline cells relative to that in differentiated somatic cells<sup>17, 18</sup>. This distinction was not as robust between rat germ cells (sperm) and somatic cells (kidney). These data confirm previous reports that vinclozolin is not directly mutagenic<sup>19</sup>, and suggest that neither the immediate phenotypic abnormalities observed in vinclozolin-lineage F1 generation offspring nor the transmission of those defects to the F2 generation can be ascribed to the direct induction of genetic mutations.



**Table 1. Mutation Frequencies in F1 Control- and Vinclozolin-Lineage Samples**

Sample Number	Tissue Type	Total number of plaque-forming units	Number of mutant plaques <sup>1</sup>	Mutation frequency +/- SE (x10 <sup>-5</sup> )
F1 Generation				
Control-lineage				
F1CLK1	Kidney	615,930	8	1.30 +/- 0.459
F1CLK2	Kidney	535,547	6	1.12 +/- 0.457
F1CLK3	Kidney	298,750	7	2.34 +/- 0.886
F1CLK4	Kidney	197,925	6	3.03 +/- 1.240
F1CLS1	Sperm	701,848	5	0.71 +/- 0.319
F1CLS2	Sperm	287,672	5	1.74 +/- 0.777
F1CLS3	Sperm	509,007	5	0.98 +/- 0.439
F1CLS4	Sperm	317,744	9	2.83 +/- 0.944
F1CLS5	Sperm	838,565	6	0.72 +/- 0.292
F1CLS6	Sperm	255,000	7	2.75 +/- 1.040
F1CLS7	Sperm	361,750	6	1.66 +/- 0.677
Vinclozolin-lineage				
F1VLK1	Kidney	371,736	6	1.61 +/- 0.659
F1VLK2	Kidney	271,845	6	2.21 +/- 0.901
F1VLK3	Kidney	310,250	5	1.61 +/- 0.721
F1VLK4	Kidney	218,275	5	2.29 +/- 1.020
F1VLK5	Kidney	288,000	5	1.74 +/- 0.776
F1VLS1	Sperm	1,323,987	9	0.68 +/- 0.227
F1VLS2	Sperm	486,858	7	1.44 +/- 0.543
F1VLS3	Sperm	253,250	5	1.97 +/- 0.883
F1VLS4	Sperm	291,250	6	2.06 +/- 0.841

<sup>1</sup>Confirmed, nonclonal mutant plaques

*Exposure to vinclozolin in utero predisposes an accelerated accumulation of point mutations detectable in a subset of F3 generation offspring* – Frequencies of mutations detected in kidney and sperm cells from vinclozolin- or control-lineage F3 generation descendants of dams exposed during pregnancy to either vehicle plus vinclozolin or vehicle alone, respectively, are shown in Table 2. Interestingly, for both the control- and vinclozolin-lineage animals the frequencies of mutations detected in the F3 generation were consistently higher than those detected in F1 generation animals. The F1 and F3 generation samples were not generated or analyzed simultaneously, however, the control and vinclozolin-exposed samples within each generation were generated and analyzed

simultaneously. Therefore, the relevant comparison in each case is between control and vinclozolin-exposed samples within the same generation.

**Table 2. Mutation Frequencies in F3 Control- and Vinclozolin-Lineage Samples**


Sample Number	Tissue Type	Total number of plaque-forming units	Number of mutant plaques <sup>1</sup>	Mutation frequency +/- SE (x10 <sup>-5</sup> )
F3 Generation				
Control-lineage				
F3CLK1	Kidney	192,021	8	4.17 +/- 1.470
F3CLK2	Kidney	344,629	20	5.80 +/- 1.300
F3CLK3	Kidney	280,976	10	3.56 +/- 1.130
F3CLK4	Kidney	408,408	14	3.43 +/- 0.916
F3CLK5	Kidney	342,510	13	3.80 +/- 1.050
F3CLK6	Kidney	229,108	9	3.93 +/- 1.310
F3CLK7	Kidney	298,833	15	5.02 +/- 1.300
F3CLS1	Sperm	233,588	10	4.28 +/- 1.350
F3CLS2	Sperm	337,211	11	3.26 +/- 0.984
F3CLS3	Sperm	363,529	7	1.93 +/- 0.728
F3CLS4	Sperm	158,172	5	3.16 +/- 1.410
Vinclozolin-lineage				
F3VLK1	Kidney	135,475	9	6.64 +/- 2.210
F3VLK2	Kidney	484,872	22	4.54 +/- 0.967
F3VLK3	Kidney	264,136	5	1.89 +/- 0.847
F3VLK4	Kidney	681,660	23	3.37 +/- 0.704
F3VLK5	Kidney	375,254	13	3.46 +/- 0.961
F3VLK6	Kidney	36,358	9	24.75 +/- 8.250
F3VLK7	Kidney	261,008	23	8.81 +/- 1.840
F3VLK8	Kidney	94,996	9	9.47 +/- 3.160
F3VLK9	Kidney	260,167	6	2.31 +/- 0.942
F3VLK10	Kidney	128,520	8	6.22 +/- 2.200
F3VLS1	Sperm	53,656	7	13.05 +/- 4.930
F3VLS2	Sperm	117,677	8	6.80 +/- 2.400
F3VLS3	Sperm	91,889	6	6.53 +/- 2.670
F3VLS4	Sperm	262,559	7	2.67 +/- 1.010
F3VLS5	Sperm	392,605	8	2.04 +/- 0.720
F3VLS6	Sperm	33,843	6	17.73 +/- 7.240
F3VLS7	Sperm	162,386	6	3.70 +/- 1.510
F3VLS8	Sperm	344,389	5	1.45 +/- 0.649

When compared to mutation frequencies detected in kidney and sperm samples from F3 generation control-lineage animals, one subset of the kidney samples (7 of 10) and one subset of the sperm samples (5 of 8) from F3 generation vinclozolin-lineage animals showed mutation frequencies that were


not statistically different from the control values, although the mutation frequencies detected in some of these F3 vinclozolin-lineage samples trended higher than those in the F3 control-lineage animals (Fig. 1B). However, another subset of kidney samples (3 of 10) and sperm samples (3 of 8) from F3 generation vinclozolin-lineage animals showed mutation frequencies that were significantly higher than the mean frequency in the corresponding control-lineage samples (marked with astrices in Fig. 1B;  $p < 0.05$ ). Indeed, mutation frequencies detected in these divergent samples were 2-13 fold higher than the mean mutation frequency detected among the corresponding F3 generation control-lineage samples. This suggests that in utero exposure to vinclozolin predisposes a subsequent accumulation of mutations at an accelerated rate in some descendants. This effect appears to occur in a gradual and stochastic manner, such that it is not detectable in any vinclozolin-lineage F1 generation offspring but is manifest in a subset of vinclozolin-lineage F3 generation descendants.

Figure 1

A F1 Generation Samples



B F3 Generation Samples



**Figure 1. Mutation frequencies in F1 and F3 generation samples.**

**A.** Mutation frequencies in kidney and sperm samples from F1 generation control- and vinclozolin-lineage animals. There were no statistically significant differences among the mutation frequencies detected in kidney or sperm samples from F1 generation control- and vinclozolin-lineage samples, except for one of the vinclozolin-lineage sperm samples (F1VLS1 – marked with an asterisk) which showed a mutation frequency that was significantly lower than the mean of the F1 generation control-lineage samples ( $p = 0.00352$ ).

**B.** Mutation frequencies in kidney and sperm samples from F3 generation control- and vinclozolin-lineage animals. A subset of both kidney and sperm samples from F3 vinclozolin-lineage descendants showed mutation frequencies that were not significantly different than the mean of the corresponding F3 generation control-lineage samples, although several of the F3 generation vinclozolin-lineage samples trended higher than the mean of the corresponding F3 generation control-lineage samples. However another subset of both kidney and sperm samples from F3 generation vinclozolin-lineage descendants showed mutation frequencies that were significantly higher than the mean of the corresponding F3 control-lineage samples. These mutation frequencies are marked with astrices, and include those found in the following samples: F3VLK6 ( $p=0.00342$ ), F3VLK7 ( $p=0.00131$ ), F3VLK8 ( $p=0.0222$ ), F3VLS1 ( $p=0.00185$ ), F3VLS2 ( $p=0.03611$ ) and F3VLS6 ( $p=0.00018$ ). F1 = samples from F1 generation descendants, F3 = samples from F3 generation descendants, CL = samples from control-lineage descendants, VL = samples from vinclozolin-lineage descendants, K = kidney samples, S = sperm samples.

The *lacI* gene from each mutant (blue) plaque recovered from each cell or tissue sample was sequenced to confirm that a mutation had occurred in each case and to determine the range of types of mutations associated with each cell sample. A comprehensive list of the position and type of each mutation detected in the *lacI* gene recovered from each set of tissues is shown in Supplementary Table S1, and a summary of the spectrum of mutations detected in each set of samples is shown in Table 3.

**Table 3. Mutation Spectra Detected in Control- and Vinclozolin-Lineage Samples**

Generation/ Tissue	Mutation Type Number/(% of Total)			
	TS <sup>1</sup>	TV <sup>2</sup>	I/D <sup>3</sup>	DBS <sup>4</sup>
<b>F1 Generation/</b>				
Control-lineage				
Kidney	6/(40.00)	2/(13.33)	6/(40.00)	1/(6.67)
Sperm	10/(40.00)	6/(24.00)	7/(28.00)	2/(8.00)
Total	16/(40.00)	8/(20.00)	13/(32.50)	3/(7.50)
Vinclozolin-lineage				
Kidney	8/(66.67)	2/(16.67)	2/(16.67)	0/(0)
Sperm	8/(50.00)	2/(12.50)	5/(31.25)	1/(6.25)
Total	16/(57.14)	4/(14.29)	7/(25.00)	1/(3.57)
<b>F3 Generation/</b>				
Control-lineage				
Kidney	17/(22.37)	11/(14.47)	46/(60.53)	2/(2.63)
Sperm	10/(26.32)	13/(34.21)	15/(39.47)	0/(0)
Total	27/(23.68)	24/(21.05)	61/(53.51)	2/(1.75)
Vinclozolin-lineage				
Kidney	27/(21.26)	15/(11.81)	81/(63.78)	4/(3.15)
Sperm	21/(47.73)	4/(9.09)	17/(38.64)	2/(4.55)
Total	48/(28.07)	19/(11.11)	98/(57.31)	6/(3.51)

<sup>1</sup>Transitions

<sup>2</sup>Transversions

<sup>3</sup>Single+ Base Insertions or Deletions

<sup>4</sup>Double+ Base Substitutions

## Discussion

The discovery of environmentally induced germline epimutations that are transmitted transgenerationally for three or more generations following exposure of only the F1 generation fetus suggests these epimutations are not corrected by the extensive epigenetic reprogramming that normally occurs in the developing germ line<sup>5, 7</sup>. Many environmentally induced epimutations (including those resulting from in utero exposure to vinclozolin) have been reported to be manifest as abnormalities in locus- or allele-specific patterns of DNA methylation<sup>20, 21, 22, 23, 24</sup>, while others appear to reflect changes in patterns of histone modifications<sup>25</sup>. However, inherited patterns of both DNA methylation and histone modifications are largely erased in the developing germline and then reset so as to provide proper epigenetic programming to support development of the subsequent generation during embryonic, fetal and postnatal stages<sup>5, 26</sup>. This germline-specific epigenetic reprogramming has the potential to correct environmentally induced epimutations, thus preventing their transmission to subsequent generations, and such a correction process has been documented in some cases<sup>12</sup>. Nevertheless, a growing number of cases of transgenerational transmission of environmentally induced epimutations have now been reported<sup>2, 11</sup>, indicating that exposure of individuals to environmental factors or stressful circumstances can induce epimutations that are transmitted transgenerationally and escape normal germline reprogramming<sup>7</sup>. Therefore, these germline epimutations appear to be sustained in a manner similar to imprinted genes<sup>20</sup>. These transgenerational epimutations have the potential to promote a novel etiology of various types of disease or abnormalities in the exposed individuals

and in their descendants, even in the absence of any ongoing exposure to the causative agent<sup>2, 4</sup>.

Alteration of DNA methylation patterns in cells of offspring exposed to vinclozolin in utero has been well documented<sup>1, 21</sup>. This suggests that vinclozolin induces primary epimutations in the form of direct alterations of DNA methylation patterns that are subsequently propagated by epigenetic transgenerational inheritance. We tested the hypothesis that in utero exposure to vinclozolin might also induce genetic mutations that could contribute to secondary epimutations in which abnormalities in epigenetic programming result from alteration of one or more genetic functions normally required to establish such programming, because secondary epimutations would be expected to contribute to transgenerational transmission of the resulting phenotype on the basis of genetic inheritance. However, our data showing no difference in mutation frequencies between F1 generation vinclozolin- and control-lineage offspring corroborate previous reports that vinclozolin is not directly mutagenic<sup>19</sup>. This argues against the likelihood that exposure to vinclozolin induces secondary epimutations.

We next investigated mutation frequencies in F3 generation vinclozolin- and control-lineage descendants of dams that were or were not exposed to vinclozolin, respectively. Surprisingly, we detected an elevated frequency of point mutations in a subset of F3 generation vinclozolin-lineage descendants that distinguished these animals from the F3 generation control-lineage animals and from the other F3 generation vinclozolin-lineage animals. Thus, our results suggest that in utero exposure to vinclozolin promotes the initial induction of primary epimutations, at least some of which have the potential to predispose an



elevated accumulation of point mutations in subsequent generations. We propose that this represents a third type of epimutation which we term a “tertiary epimutation” and define as an initial disruption of epigenetic programming that leads to a subsequent change in the frequency of genetic mutations. Our finding that the frequency of point mutations is not increased in vinclozolin-lineage F1 generation offspring, but is increased in a subset of vinclozolin-lineage F3 descendants exemplifies the expected gradual inheritance pattern of a tertiary epimutation. These results are consistent with a recent report of an increase in copy number variations (CNV) in F3 generation, but not F1 generation descendants of vinclozolin-exposed dams (27). These observations corroborate previous reports suggesting that disruption of epigenetic programming can predispose multiple types of genetic aberrations<sup>28, 29, 30, 31, 32, 33, 34, 35, 36, 37</sup>.

Abnormalities in epigenetic programming could predispose genome instability through a variety of mechanisms. The most well documented example is predisposition of C-to-T transitions via deamination of methylated cytosines<sup>18, 28, 29, 38</sup>. Thus, a change in the methylation status of a CpG dinucleotide, particularly the addition of DNA methylation where it normally does not occur, typically increases the likelihood that a C-to-T transition will change a G-C base pair into an A-T base pair. However, we did not observe a significant increase in C-to-T transitions in samples from F3 generation vinclozolin-lineage animals (Table 3), so this does not appear to be the primary source of the increased mutation frequency we observed in these samples.

It is well established that epigenetic programming regulates chromatin structure<sup>39, 40</sup> and that more or less condensed chromatin appears less or more

susceptible, respectively, to either spontaneous or induced mutagenesis<sup>41, 42</sup>.

We have no data describing the extent of chromatin condensation associated with the *lacI* mutation-reporter transgene in kidney or sperm cells from F3 generation vinclozolin-lineage animals, so cannot comment on whether or not this source of accelerated mutagenesis may have contributed to the elevated mutation frequencies in a subset of F3 generation vinclozolin-lineage animals.

Finally, it has been shown that specific cellular states, such as those that distinguish pluripotent and differentiated cell types, or germ and somatic cell types are correlated with more or less enhanced maintenance of genetic integrity. This is at least partially controlled by epigenetic mechanisms that coordinate the function of different gene networks in cells that regulate pluripotency and genetic integrity<sup>43</sup>. To the extent that this type of coordinate regulation normally governs the relative level of expression of genetic integrity (DNA repair or cell death) genes, disruptions of epigenetic programming could alter maintenance of genetic integrity resulting in the subsequent accumulation of point mutations at an accelerated rate. This would only occur if regulation of a relevant gene network was impacted by the initial epigenetic disruption, which would normally occur stochastically, such that changes in mutation frequencies would be expected to occur in only a subset of descendants of animals exposed to the initial disruptor. Our observation that only a subset of F3 vinclozolin-lineage descendants displayed significant increases in mutation frequency is consistent with this notion. In addition, a multiple step process of this sort (initial disruption of the epigenome → dysregulation of a genetic integrity gene network → an increase in the rate at which spontaneous point mutations are

accumulated) would likely lead to a gradual increase in mutation frequency. This is consistent with our observation of a detectable increase in mutation frequency in F3 generation, but not in F1 generation vinclozolin-lineage descendants.

Taken together, our results support a novel mechanism by which initial epimutations can predispose a subsequent accelerated accumulation of genetic mutations, and such tertiary epimutations could contribute to the epigenetic transgenerational transmission of phenotypes on the basis of either epigenetic or genetic inheritance, or both. The addition of tertiary epimutations to the list of possible scenarios by which heritable phenotypic alterations can be introduced and/or transmitted completes the options for potential combinations of genetic and epigenetic events involved in this process. It is likely that various combinations of genetic and epigenetic mechanisms of transmission are involved in the etiology of epigenetic transgenerational inheritance.

## Methods

*Acquisition and exposure of rats and recovery of tissues* – Big Blue rats carrying the *lacI* mutation-reporter transgene<sup>44</sup> were obtained from Stratagene (La Jolla, CA). In the Skinner lab the Big Blue rats at 70 to 100 days of age were fed ad lib with a standard rat diet and ad lib tap water. To obtain timed-pregnant females, female rats in proestrus were pair-mated with male rats. Sperm-positive (day 0) rats were monitored for diestrus and body weight. On days 8–14 of gestation, the females were administered daily intraperitoneal injections of vinclozolin (100 mg/kg BW/day) or dimethyl sulfoxide (vehicle) as a control as described<sup>45</sup>. Generally sibling females were used for the control and vinclozolin lineage F0 generation females, respectively. In addition, sibling F0 generation males were used to generate control and exposure lineage offspring. Vinclozolin was obtained from Chem Service Inc. (West Chester, PA), and was injected in a 200 microliter DMSO/sesame oil vehicle as previously described<sup>46</sup>. The initial gestating female rats and the males to which they were mated were designated as the F0 generation. Offspring of F0 generation matings formed the F1 generation. Non-sibling females and males aged 70-90 days from F1 generation control or vinclozolin lineages were bred to generate F2 generation offspring. F2 generation rats were then bred to obtain F3 generation offspring. Only the F0 generation gestating female was directly treated transiently with vinclozolin. Different F0 generation females were used for the different experiments and one male per litter was selected for the individual animals for each specific experiment. Control and vinclozolin lineage animals were housed in the same

room and racks with identical lighting and food + water supply as previously described<sup>4, 46, 47</sup>.

To obtain sperm samples, the epididymis was dissected free of connective tissue and a small cut was made in the cauda portion, which was then placed in 5 ml of F12 culture medium containing 0.1% bovine serum albumin for 10 minutes at 37°C to allow sperm to emerge from the tissue and then kept at 4°C to immobilize the sperm. The epididymal tissue was minced and the released sperm centrifuged at 13, 000 x *g* and stored in fresh nucleus isolation medium buffer at -70°C as described<sup>4, 46, 47</sup>. Kidneys were also dissected and snap frozen at -70°C. Each tissue or cell sample was shipped to the McCarrey lab on dry ice for further analysis (see below). All experimental protocols for the procedures with rats were pre-approved by the Washington State University Institutional Animal Care and Use Committee (IACUC approval # 02568-039), and were carried out in accordance with the approved guidelines.

*Recovery of the mutation-reporter transgene* – High molecular weight DNA was prepared from each tissue or cell sample using the RecoverEase kit protocol from Stratagene with modifications as described<sup>18, 48</sup>. Briefly, each sample was homogenized with a Dounce tissue homogenizer, filtered through a 100 µm filter (Millipore, Billerica, MA), subjected to digestion with ribonuclease (RNase-it, Stratagene) and proteinase K, then drop dialyzed against 1X TE using a 0.025 µm dialysis membrane (Millipore).

*Detection and confirmation of mutations in the lacI mutation-reporter transgene –*

High molecular weight DNA recovered from each kidney or sperm sample was subjected to a phage packaging reaction using Transpack packaging extract (Stratagene) following the manufacturer's protocol. Resulting infectious phage particles were plated onto a 25cm x 25cm lawn of SCS-8 E. coli cells to facilitate formation of phage plaques (up to 15,000 plaque forming units [pfu]/plate). The *lacI* gene normally encodes a repressor of the *lac* operon that inhibits production of beta galactosidase by infected E. coli<sup>49</sup>. However, point mutations incurred in the *lacI* gene while it was present as a transgene in the cells of the Big Blue rats can result in defective function of the *lac* repressor such that it fails to repress expression of the *lac* operon, resulting in production of beta galactosidase by E. coli infected with phage carrying a mutated *lacI* gene. The addition of X-gal and IPTG to the plating medium facilitated a blue/clear color selection method to distinguish rare mutant phage expressing beta galactosidase (blue plaques) from abundant wild type phage in which expression of beta galactosidase remained repressed on each plate (clear plaques). Plaques displaying an apparent mutant (blue) phenotype were then picked and re-plated to confirm the mutant phenotype in  $\geq 50\%$  of the resulting phage. Plaques carrying an abundance of mutant phage were then prepared for DNA sequencing to confirm the presence of a mutation at the molecular level and to determine the position and type of mutation present.

*Determination of the frequency and spectrum of mutations in each tissue or cell*

*sample* – DNA sequence data from each mutant plaque was used to determine

the final frequency of spontaneous point mutations in each sample. Only confirmed independent (non-clonal) mutations were used to calculate the final frequency of mutations. Thus, if the same mutation in the same position within the *lacI* gene was detected more than once in the same DNA sample, it was assumed that this represented a single original mutation that was subsequently clonally amplified in the tissue or cell type, and such 'clonal' mutations were counted as a single mutation no matter how many times they were detected in a particular sample. Mutation frequencies were calculated by dividing the number of distinct, confirmed, non-clonal mutant plaques by the total number of pfu examined from each DNA sample. In general, sufficient total numbers of pfu were examined to identify at least five separate mutant plaques from each sample to facilitate statistical comparisons of the data from different samples. The DNA sequence data were also used to establish a mutation spectrum for each sample by cataloguing the relative prevalence of different types of point mutations detected in each sample, including base substitutions – transitions or transversions, small insertions, small deletions, or multiple base changes.

*Determination of statistical significance of differences in mutation frequencies or spectra* – Numbers of mutations were analyzed by a Poisson model with parameter estimates obtained by the method of maximum likelihood<sup>50</sup>. Because of the low expected frequencies, exact P-values were calculated by the exact conditional test for Poisson variables to compare differences between mutation frequencies, using the Exactci package implemented in R<sup>51, 52</sup>.  $P \leq 0.05$  was considered statistically significant.

## References

1. Anway, M. D., Cupp, A. S., Uzumcu, M. & Skinner M. K. Epigenetic transgenerational actions of endocrine disruptors and male fertility. *Science* **308**, 1466-1469 (2005).
2. Nilsson, E. E., & Skinner, M. K. Environmentally Induced Epigenetic Transgenerational Inheritance of Reproductive Disease. *Biology of reproduction* **93**, 145 (2015).
3. Skinner, M. K. Endocrine disruptor induction of epigenetic transgenerational inheritance of disease. *Molecular and cellular endocrinology* **398**, 4-12 (2014).
4. Skinner, M. K., Manikkam, M. & Guerrero-Bosagna, C. Epigenetic transgenerational actions of environmental factors in disease etiology. *Trends Endocrinol Metab* **21**, 214-222 (2010).
5. Lee, H. J., Hore, T. A. & Reik, W. Reprogramming the methylome: erasing memory and creating diversity. *Cell Stem Cell* **14**, 710-719 (2014).
6. McCarrey, J. R. The epigenome as a target for heritable environmental disruptions of cellular function. *Molecular and cellular endocrinology* **354**, 9-15 (2012).
7. McCarrey, J. R. Distinctions between transgenerational and non-transgenerational epimutations. *Molecular and cellular endocrinology* **398**, 13-23 (2014).
8. McCarrey, J. R. EPIGENETICS. The epigenome--a family affair. *Science* **350**, 634-635 (2015).



9. Skinner, M. K. What is an epigenetic transgenerational phenotype? F3 or F2. *Reproductive toxicology* **25**, 2-6 (2008).
10. Rando, O. J. Intergenerational Transfer of Epigenetic Information in Sperm. *Cold Spring Harb Perspect Med*, (2016).
11. Skinner, M. K. Endocrine disruptors in 2015: Epigenetic transgenerational inheritance. *Nat Rev Endocrinol* **12**, 68-70 (2016).
12. de Waal, E. *et al.* Primary epimutations introduced during intracytoplasmic sperm injection (ICSI) are corrected by germline-specific epigenetic reprogramming. *Proceedings of the National Academy of Sciences of the United States of America* **109**, 4163-4168 (2012).
13. Whitelaw, N. C. & Whitelaw, E. Transgenerational epigenetic inheritance in health and disease. *Curr Opin Genet Dev* **18**, 273-279 (2008).
14. Kohler, S. W. *et al.* Analysis of spontaneous and induced mutations in transgenic mice using a lambda ZAP/lacI shuttle vector. *Environmental and molecular mutagenesis* **18**, 316-321 (1991).
15. Kohler, S. W. *et al.* Spectra of spontaneous and mutagen-induced mutations in the lacI gene in transgenic mice. *Proceedings of the National Academy of Sciences of the United States of America* **88**, 7958-7962 (1991).
16. Guerrero-Bosagna, C. *et al.* Epigenetic Transgenerational Inheritance of Vinclozolin Induced Mouse Adult Onset Disease and Associated Sperm Epigenome Biomarkers. *Reproductive toxicology* **34**, 694-707 (2012).

17. Walter, C. A., Intano, G. W., McCarrey, J. R., McMahan, C. A. & Walter, R. B. Mutation frequency declines during spermatogenesis in young mice but increases in old mice. *Proceedings of the National Academy of Sciences of the United States of America* **95**, 10015-10019 (1998).
18. Murphey, P., McLean, D. J., McMahan, C. A., Walter, C. A. & McCarrey, J. R. Enhanced genetic integrity in mouse germ cells. *Biology of reproduction* **88**, 6 (2013).
19. Hrelia, P. *et al.* The genetic and non-genetic toxicity of the fungicide Vinclozolin. *Mutagenesis* **11**, 445-453 (1996).
20. Jirtle, R. L. & Skinner, M. K. Environmental epigenomics and disease susceptibility. *Nature reviews. Genetics* **8**, 253-262 (2007).
21. Skinner, M. K. & Guerrero-Bosagna, C. Role of CpG Deserts in the Epigenetic Transgenerational Inheritance of Differential DNA Methylation Regions. *BMC Genomics* **15**, 692 (2014).
22. Youngson, N. A. *et al.* Obesity-induced sperm DNA methylation changes at satellite repeats are reprogrammed in rat offspring. *Asian J Androl*, (2015).
23. Ma, J. *et al.* Ancestral TCDD exposure promotes epigenetic transgenerational inheritance of imprinted gene Igf2: Methylation status and DNMTs. *Toxicology and applied pharmacology* **289**, 193-202 (2015).
24. Blaze, J. & Roth, T. L. Evidence from clinical and animal model studies of the long-term and transgenerational impact of stress on DNA methylation. *Semin Cell Dev Biol* **43**, 76-84 (2015).

25. Siklenka, K. *et al.* Disruption of histone methylation in developing sperm impairs offspring health transgenerationally. *Science* **350**, aab2006 (2015).
26. Peters, A. H. & Schubeler, D. Methylation of histones: playing memory with DNA. *Current opinion in cell biology* **17**, 230-238 (2005).
27. Skinner, M. K., Guerrero-Bosagna, C. & Haque, M. M. Environmentally Induced Epigenetic Transgenerational Inheritance of Sperm Epimutations Promote Genetic Mutations. *Epigenetics : official journal of the DNA Methylation Society* **10**, 762-771 (2015).
28. Sved, J. & Bird, A. The expected equilibrium of the CpG dinucleotide in vertebrate genomes under a mutation model. *Proceedings of the National Academy of Sciences of the United States of America* **87**, 4692-4696 (1990).
29. Lutsenko, E. & Bhagwat, A. S. Principal causes of hot spots for cytosine to thymine mutations at sites of cytosine methylation in growing cells. A model, its experimental support and implications. *Mutat Res* **437**, 11-20 (1999).
30. Becker, C. *et al.* Spontaneous epigenetic variation in the *Arabidopsis thaliana* methylome. *Nature* **480**, 245-249 (2011).
31. Tang, M. H. *et al.* Major chromosomal breakpoint intervals in breast cancer co-localize with differentially methylated regions. *Front Oncol* **2**, 197 (2012).
32. Macia, A. *et al.* Epigenetic control of retrotransposon expression in human embryonic stem cells. *Molecular and cellular biology* **31**, 300-316 (2011).

33. Feinberg, A. P. The epigenetics of cancer etiology. *Semin Cancer Biol* **14**, 427-432 (2004).
34. You, J. S. & Jones, P. A. Cancer genetics and epigenetics: two sides of the same coin? *Cancer Cell* **22**, 9-20 (2012).
35. Almal, S. H. & Padh, H. Implications of gene copy-number variation in health and diseases. *J Hum Genet* **57**, 6-13 (2012).
36. Wu, J. *et al.* Copy Number Variation detection from 1000 Genomes Project exon capture sequencing data. *BMC bioinformatics* **13**, 305 (2012).
37. Miyake, K. *et al.* Comparison of Genomic and Epigenomic Expression in Monozygotic Twins Discordant for Rett Syndrome. *PloS one* **8**, e66729 (2013).
38. Collins, D. W. & Jukes, T. H. Rates of transition and transversion in coding sequences since the human-rodent divergence. *Genomics* **20**, 386-396 (1994).
39. Rea, S. *et al.* Regulation of chromatin structure by site-specific histone H3 methyltransferases. *Nature* **406**, 593-599 (2000).
40. Hashimshony, T., Zhang, J., Keshet, I., Bustin, M. & Cedar, H. The role of DNA methylation in setting up chromatin structure during development. *Nat Genet* **34**, 187-192 (2003).
41. Smerdon, M. J. DNA repair and the role of chromatin structure. *Current opinion in cell biology* **3**, 422-428 (1991).
42. Friedberg, E. C., Walker, G. C., Siede, W. & Schultz, R. A. *DNA repair and mutagenesis* (ASM Press, Washington DC, ed. 2, 2006).

43. Cooper, D. J., Walter, C. A. & McCarrey, J. R. Co-regulation of pluripotency and genetic integrity at the genomic level. *Stem Cell Res* **13**, 508-519 (2014).
44. Dycaico, M. J. *et al.* The use of shuttle vectors for mutation analysis in transgenic mice and rats. *Mutat Res* **307**, 461-478 (1994).
45. Nilsson, E. E., Anway, M. D., Stanfield, J. & Skinner, M. K. Transgenerational epigenetic effects of the endocrine disruptor vinclozolin on pregnancies and female adult onset disease. *Reproduction* **135**, 713-721 (2008).
46. Manikkam, M., Guerrero-Bosagna, C., Tracey, R., Haque, M. M. & Skinner, M. K. Transgenerational actions of environmental compounds on reproductive disease and identification of epigenetic biomarkers of ancestral exposures. *PloS one* **7**, e31901 (2012).
47. Anway, M. D., Leathers, C. & Skinner, M. K. Endocrine disruptor vinclozolin induced epigenetic transgenerational adult-onset disease. *Endocrinology* **147**, 5515-5523 (2006).
48. Caperton, L. *et al.* Assisted reproductive technologies do not alter mutation frequency or spectrum. *Proceedings of the National Academy of Sciences of the United States of America* **104**, 5085-5090 (2007).
49. Muller-Hill, B. Lac repressor and lac operator. *Progress in biophysics and molecular biology* **30**, 227-252 (1975).
50. Agresti, A. *Categorical Data Analysis*. (Wiley, New York, 2002).
51. Fay, M. Two-sided Exact Tests and Matching Confidence Intervals for Discrete Data. *R Journal*, 53-58 (2010).

52. Hirji, K. *Exact Analysis of Discrete Data*. (Chapman and Hall/CRC, New York, 2006).

### **Acknowledgements**

JRM is the Kleberg Distinguished University Chair in Cellular & Molecular Biology at UTSA. MKS is the Eastlick Distinguished Professor at WSU. We acknowledge the assistance of Ms. Heather Johnson in preparation of the manuscript. The research was supported by a grant from the Kleberg Foundation to JRM, an NIH grant to MKS and a John Templeton Foundation grant to MKS and JRM.

### **Author information**

#### **Affiliations**

**Department of Biology, University of Texas at San Antonio, San Antonio, Texas 78249, USA**

John R. McCarrey, Jake D. Lehle, Seetha S. Raju, Yufeng Wang

**Center for Reproductive Biology, School of Biological Sciences, Washington State University, Pullman, Washington 99164, USA**

Eric E. Nilsson, Michael K. Skinner

**Contributions**

J.R.M. and M.K.S. designed the study, interpreted the results and wrote the manuscript. J.D.L. and S.S.R. conducted analyses of mutation frequencies. Y.W. conducted all statistical analyses. E.E.N. oversaw and conducted all vinclozolin exposures.

**Competing financial interests**

The authors declare no competing financial interests.

**Corresponding author**

Correspondence to: John R. McCarrey

**Supplementary information**

Table S1